Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H18ClN3 |
Molecular Weight | 299.798 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=C(Cl)NC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CC#N)CN2C
InChI
InChIKey=JKAHWGPTNVUTNB-IXPVHAAZSA-N
InChI=1S/C17H18ClN3/c1-21-9-10(5-6-19)7-12-11-3-2-4-14-16(11)13(8-15(12)21)17(18)20-14/h2-4,10,12,15,20H,5,7-9H2,1H3/t10-,12-,15-/m1/s1
Lergotrile is an ergot alkaloid clinically effective in the treatment of Parkinson’s disease. The in vivo dopaminergic effects of lergotrile are similar to those produced by the direct acting dopaminergic agonists apomorphine or L-DOPA. Like apomorphine or L-DOPA, lergotrile decreases prolactin secretion, produces stereotyped behavior in intact rats, and causes contralateral rotation in rats with uniIateral 6-hydroxydopamine lesions of substantia nigra. However, unlike apomorphine or L-DOPA, lergotrile does not activate dopamine sensitive adenylate cyclase in vitro. Side effects of lergotrile included exacerbation of hallucinations, dyskinesias, hypotension, and alterations in liver function tests. Although lergotrile, when added to levodopa, has a definite antiparkinsonian effect, the incidence of adverse effects, particularly hepatotoxicity, makes it unlikely that this ergot alkaloid will become widely available for the treatment of Parkinson’s disease.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Dopaminergic effects of lergotrile: possible involvement of a metabolite. | 1980 Jun |
|
Clinical pharmacokinetics of ergotamine, dihydroergotamine, ergotoxine, bromocriptine, methysergide, and lergotrile. | 1983 Mar |
|
Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. | 1983 May |
|
Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions. | 1986 Mar |
|
Aminergic regulation of neuroendocrinological functions: theoretical background and some clinical examples. | 1987 |
|
D-1 and D-2 agonists in Parkinson's disease. | 1987 Aug |
|
Stimulus properties of dopaminergic drugs: comparisons involving selective agonists and antagonists. | 1988 |
|
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. | 1993 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6105627
Single dose - 0.05 - 1.5 mg/kg
Route of Administration:
Intraperitoneal
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3594
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
O68JXU1W09
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
C031875
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
Lergotrile
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
DTXSID701043282
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
100000082591
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL80937
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
SUB08438MIG
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
6918447
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
36945-03-6
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY | |||
|
C81079
Created by
admin on Fri Dec 15 16:39:22 GMT 2023 , Edited by admin on Fri Dec 15 16:39:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)